Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02637960 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
A Phase 2 study, sponsored by Vantia.
- Completed
- Registry status
- Phase 2
- Development phase
- 432
- Enrollment target
NCT02637960: Completed Phase 2 study, sponsored by Vantia.
NCT02637960 is a Phase 2 study that has completed, run by Vantia. The registered enrollment target is 432 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (225% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02637960, a Phase 2 study, has completed, sponsored by Vantia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 432 participants
- Enrollment target
Study Summary
This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.
Interventions
- DRUG Placebo
- DRUG Fedovapagon 2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
What the finished NCT02637960 record still lists
NCT02637960 is an interventional study that assigns participants to a tested intervention. The registered 432 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (225% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02637960 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02637960 about?
NCT02637960 is a clinical study titled "Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)". This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.
What is the current status of trial NCT02637960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 432 participants. The study started on 2016-03. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02637960?
The interventions under investigation include: Placebo (DRUG), Fedovapagon 2 mg (DRUG).
Who is sponsoring clinical trial NCT02637960?
This trial is sponsored by Vantia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02637960's enrollment target sits among peer trials
432 90th of 2000 higher than 1,911 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
- NCT05806164 · 432 participants · Phase 4
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia